Tags

Type your tag names separated by a space and hit enter

Effect of pharmaceutical care on the treatment of COVID-19: A protocol for systematic review and meta analysis.
Medicine (Baltimore). 2020 Nov 25; 99(48):e23377.M

Abstract

BACKGROUND

We aimed to conduct a meta-analysis to assess the effect of pharmaceutical care on the treatment of coronavirus disease 2019 (COVID-19).

METHODS

All case-controlled studies related to pharmaceutical care on the treatment of COVID-19 will be included in this review. We will use index words related to pharmaceutical care and COVID-19 to perform literature searches in PubMed, Embase, MEDLINE, CNKI, and Wanfang databases, to include articles indexed as of October 20, 2020 in English and Chinese language. Two reviewers will select trials independently for inclusion and assess trial quality. Two pairs of review authors will independently extract information for each included trials. Primary outcomes are clinical outcomes, average hospital stays, costs, patient satisfaction, and incidence of adverse drug reactions. We will evaluate the risk of bias of the included studies based on Cochrane assessment tool. Revman 5.3 (the Cochrane collaboration, Oxford, UK) will be used for heterogeneity assessment, generating funnel-plots, data synthesis, subgroup analysis, and sensitivity analysis.

RESULTS

We will provide targeted and practical results assessing the effect of pharmaceutical care on the treatment of COVID-19.

CONCLUSION

The stronger evidence about the effect of pharmaceutical care on the treatment of COVID-19 will be provided for clinicians.

SYSTEMATIC REVIEW REGISTRATION NUMBER

PROSPERO CRD42020214223 ETHICS AND DISSEMINATION:: There is no need for ethical approval, and the review will be reported in a peer-reviewed journal.

Authors+Show Affiliations

Department of Clinical Pharmacy.Department of Pharmacy, Jingjiang People's Hospital, the Seventh Affiliated Hospital of Yangzhou University, Jingjiang, Jiangsu, China.Department of Pharmacy, Jingjiang People's Hospital, the Seventh Affiliated Hospital of Yangzhou University, Jingjiang, Jiangsu, China.Department of Clinical Pharmacy.Department of Clinical Pharmacy.Department of Clinical Pharmacy.Department of Clinical Pharmacy.Department of Clinical Pharmacy.Department of Clinical Pharmacy.Department of Clinical Pharmacy.Department of Clinical Pharmacy.Department of Pharmacy, Jingjiang People's Hospital, the Seventh Affiliated Hospital of Yangzhou University, Jingjiang, Jiangsu, China.

Pub Type(s)

Journal Article
Meta-Analysis
Systematic Review

Language

eng

PubMed ID

33235111

Citation

Niu, Jiali, et al. "Effect of Pharmaceutical Care On the Treatment of COVID-19: a Protocol for Systematic Review and Meta Analysis." Medicine, vol. 99, no. 48, 2020, pp. e23377.
Niu J, Chen H, Chen K, et al. Effect of pharmaceutical care on the treatment of COVID-19: A protocol for systematic review and meta analysis. Medicine (Baltimore). 2020;99(48):e23377.
Niu, J., Chen, H., Chen, K., Liu, Y., Ju, F., Xue, T., Yin, D., Li, C., Yin, C., Jiao, L., Zhao, G., & Huang, J. (2020). Effect of pharmaceutical care on the treatment of COVID-19: A protocol for systematic review and meta analysis. Medicine, 99(48), e23377. https://doi.org/10.1097/MD.0000000000023377
Niu J, et al. Effect of Pharmaceutical Care On the Treatment of COVID-19: a Protocol for Systematic Review and Meta Analysis. Medicine (Baltimore). 2020 Nov 25;99(48):e23377. PubMed PMID: 33235111.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of pharmaceutical care on the treatment of COVID-19: A protocol for systematic review and meta analysis. AU - Niu,Jiali, AU - Chen,Hongjun, AU - Chen,Kaixia, AU - Liu,Yin, AU - Ju,Feng, AU - Xue,Ting, AU - Yin,Dengyang, AU - Li,Chaoqun, AU - Yin,Chunxia, AU - Jiao,Lingyun, AU - Zhao,Guangyu, AU - Huang,Jixun, PY - 2020/11/25/entrez PY - 2020/11/26/pubmed PY - 2020/11/26/medline SP - e23377 EP - e23377 JF - Medicine JO - Medicine (Baltimore) VL - 99 IS - 48 N2 - BACKGROUND: We aimed to conduct a meta-analysis to assess the effect of pharmaceutical care on the treatment of coronavirus disease 2019 (COVID-19). METHODS: All case-controlled studies related to pharmaceutical care on the treatment of COVID-19 will be included in this review. We will use index words related to pharmaceutical care and COVID-19 to perform literature searches in PubMed, Embase, MEDLINE, CNKI, and Wanfang databases, to include articles indexed as of October 20, 2020 in English and Chinese language. Two reviewers will select trials independently for inclusion and assess trial quality. Two pairs of review authors will independently extract information for each included trials. Primary outcomes are clinical outcomes, average hospital stays, costs, patient satisfaction, and incidence of adverse drug reactions. We will evaluate the risk of bias of the included studies based on Cochrane assessment tool. Revman 5.3 (the Cochrane collaboration, Oxford, UK) will be used for heterogeneity assessment, generating funnel-plots, data synthesis, subgroup analysis, and sensitivity analysis. RESULTS: We will provide targeted and practical results assessing the effect of pharmaceutical care on the treatment of COVID-19. CONCLUSION: The stronger evidence about the effect of pharmaceutical care on the treatment of COVID-19 will be provided for clinicians. SYSTEMATIC REVIEW REGISTRATION NUMBER: PROSPERO CRD42020214223 ETHICS AND DISSEMINATION:: There is no need for ethical approval, and the review will be reported in a peer-reviewed journal. SN - 1536-5964 UR - https://www.unboundmedicine.com/medline/citation/33235111/Effect_of_pharmaceutical_care_on_the_treatment_of_COVID_19:_A_protocol_for_systematic_review_and_meta_analysis_ L2 - https://doi.org/10.1097/MD.0000000000023377 DB - PRIME DP - Unbound Medicine ER -